All News

24 October 2007

GlaxoSmithKline And Tolerx Form Worldwide Collaboration For Development And Commercialization Of Novel MedicationAntibodies

24 October 2007

Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC ConferenceAntibodies

20 October 2007

BioWa Announces Licensing of POTELLIGENT(R) Technology by GlaxoSmithKline (GSK)Antibodies

19 October 2007

Micromet Receives Regulatory Approval to Conduct a Phase 2 Clinical Trial Investigating MT103 (MEDI-538) in Patients with Acute Lymphoblastic LeukemiaAntibodies

19 October 2007

Lilly and MacroGenics Announce Licensing and Collaboration AgreementAntibodies

18 October 2007

Abbott Scientists Create One Molecule With Two Antibody FunctionsAntibodies

18 October 2007

Merck Serono Announces Joint Agreement with ImClone and Bristol-Myers Squibb for Erbitux in JapanAntibodies

17 October 2007

ImmunoGen, Inc. Earns Milestone with Start of SAR3419 Clinical TestingAntibodies

17 October 2007

Scientists Show Monoclonal Antibody Leads to Repair of Myelin Sheath in Laboratory Study of Multiple SclerosisAntibodies

16 October 2007

Medimmune and Crucell announce collaboration to develop new antibodies for the treatment and prevention of hospital-acquired bacterial infectionAntibodies

16 October 2007

Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple SclerosisAntibodies

16 October 2007

Bradmer provides Phase III Neuradiab trial update and guidanceAntibodies

12 October 2007

WILEX’ second product enters Phase III trial: IND approval from FDA for registration trial with CA9-SCANAntibodies

12 October 2007

Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta TherapyAntibodies

12 October 2007

Genmab Amends HuMax-CD4 Pivotal Study in CTCLAntibodies

9 October 2007

MorphoSys Enters Therapeutic Research Collaboration on Novel Target Molecule with Genesis ResearchAntibodies

6 October 2007

Argenes initiates Phase I clinical study of ARG098 (anti-Fas IgM monoclonal antibody), a novel therapeutics for rheumatoid arthritis, in EuropeAntibodies

6 October 2007

New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrine’s Anti-PS Technology PlatformAntibodies

5 October 2007

ZymoGenetics and Merck Serono Receive FDA Special Protocol Assessment for Atacicept Pivotal Study in Lupus NephritisAntibodies

4 October 2007

Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved PsoriasisAntibodies

4 October 2007

Crucell presents Phase I results rabies antibody cocktail showing safety and ability to protectAntibodies

3 October 2007

Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports Use as a Single Agent in Patients with Advanced Colorectal CancerAntibodies

3 October 2007

Roche Files CTA for Third Genmab AntibodyAntibodies

2 October 2007

Regeneron Announces Positive Primary Endpoint Results from a Phase 2 Study of VEGF Trap-Eye in Age-related Macular DegenerationAntibodies

1 October 2007

Preclinical Study Published in Nature Medicine Shows Anti-LINGO-1 AntibodyPromotes RemyelinationAntibodies

28 September 2007

Crucell discovers human monoclonal antibodies for the prevention and treatment of the avian flu virusAntibodies

28 September 2007

Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm StudyAntibodies

27 September 2007

Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple SclerosisAntibodies

27 September 2007

Herceptin eradicates tumours and may reduce the need for mastectomies in women with inflammatory HER2-positive breast cancer â€“ one of the most aggressive and fastest growing forms of the diseaseAntibodies

26 September 2007

Biotie has started the first phase I clinical trial with its fully human VAP-1 monoclonal antibody as it has received the final regulatory approval to do soAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Report Package: Bispecific Antibodies

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

B7-H4 Targeted Antibody Therapy Pipeline Review

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists